BioAge Investors Lose Last Bid At Obesity Drug-Linked Suit

By Sydney Price · March 3, 2026, 8:37 PM EST

Biopharmaceutical company BioAge Labs Inc. has escaped a suit accusing it of damaging investors by unexpectedly halting a clinical trial for a weight loss drug, with a California federal judge finding...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

In Re BioAge Labs, Inc., Securities Litigation

Case Number

Court

California Northern

Nature of Suit

Securities/Commodities

Date Filed

January 07, 2025

Recent Articles By Sydney

February 03, 2026
Masimo Investors' $34M Deal In Revenue Suit Gets Initial OK
January 30, 2026
SelectQuote Execs Face Investor Suit Over Kickback Probe
January 16, 2026
SEC Fines Biopharma Co. Execs Over Hidden FDA Findings
January 16, 2026
Lifecore Investors Ink $3.8M Deal In Accounting Controls Suit
January 09, 2026
Ex-Doximity Exec Cops To $2.5M Insider Trading Scheme
January 08, 2026
Ardent Health Investors Sue Over Revenue Accounting Issues
December 12, 2025
Molina Investor Sues Board Over Insurer's Guidance Cuts
December 10, 2025
Diagnostic Co. Agrees To Oversight Reforms In Derivative Suit
December 04, 2025
Medical Device Co. Faces Investor Suit Over IV Pump Issues
November 20, 2025
DocGo Investors Get First OK For $12.5M Settlement